Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systematic Review and Meta-analysis
- PMID: 33074898
- DOI: 10.1097/SLA.0000000000004350
Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systematic Review and Meta-analysis
Abstract
Objective: To compare the oncologic outcomes of liver resection (LR) and local ablation therapies for HCC.
Summary of background data: Although several studies have compared LR and local ablation therapies, the optimal treatment of choice for HCC within the Milan criteria remains controversial.
Methods: We systemically searched the MEDLINE, Embase, and Cochrane Library databases for randomized control trials (RCTs) and matched nonrandomized trials (NRTs) that compared LR and local ablation therapies for HCC within the Milan criteria. The primary outcome was overall survival (OS). Secondary outcomes were recurrence free survival (RFS) and recurrence pattern.
Results: A total of 7 RCTs and 18 matched NRTs, involving 2865 patients in the LR group and 2764 patients in the local ablation therapy group [RFA, MWA, RFA plus trans-arterial chemoembolization (TACE)], were included. Although there was no significant difference in OS between LR and RFA, LR showed a significantly better 5-year RFS than RFA in the analysis of RCTs (hazards ratio: 0.75; 95% confidence interval: 0.62-0.92; P = 0.006). The RFA group showed a significantly higher local recurrence than the LR group in both analyses of RCTs and NRTs. Additionally, the LR group showed better OS and RFS than the MWA or RFA plus TACE groups.
Conclusion: Our meta-analysis showed that LR was superior to RFA in terms of RFS and incidence of local recurrence. Moreover, LR showed better oncologic outcomes than MWA or RFA plus TACE.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors report no conflicts of interest.
Comment in
-
Comment on Regarding Manuscript "Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systemic Review and Meta-analysis".Ann Surg. 2021 Dec 1;274(6):e871-e872. doi: 10.1097/SLA.0000000000004746. Ann Surg. 2021. PMID: 33443897 No abstract available.
-
Response to the Comment on Regarding Manuscript "Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within Milan Criteria: A Systemic Review and Meta-analysis".Ann Surg. 2021 Dec 1;274(6):e872. doi: 10.1097/SLA.0000000000004737. Ann Surg. 2021. PMID: 33443902 No abstract available.
Similar articles
-
Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis.Int J Surg. 2025 May 1;111(5):3456-3466. doi: 10.1097/JS9.0000000000002302. Int J Surg. 2025. PMID: 39998503 Free PMC article.
-
Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis.Korean J Radiol. 2018 Jul-Aug;19(4):613-622. doi: 10.3348/kjr.2018.19.4.613. Epub 2018 Jun 14. Korean J Radiol. 2018. PMID: 29962868 Free PMC article.
-
Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies.World J Surg Oncol. 2024 Feb 19;22(1):56. doi: 10.1186/s12957-024-03330-8. World J Surg Oncol. 2024. PMID: 38369480 Free PMC article.
-
Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis.Eur J Surg Oncol. 2020 May;46(5):763-771. doi: 10.1016/j.ejso.2020.01.004. Epub 2020 Jan 7. Eur J Surg Oncol. 2020. PMID: 31937433 Review.
-
Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis.Int J Hyperthermia. 2019;36(1):264-272. doi: 10.1080/02656736.2018.1562571. Epub 2019 Jan 24. Int J Hyperthermia. 2019. PMID: 30676100
Cited by
-
Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis.J Hepatocell Carcinoma. 2023 Sep 6;10:1465-1477. doi: 10.2147/JHC.S424616. eCollection 2023. J Hepatocell Carcinoma. 2023. PMID: 37701564 Free PMC article.
-
LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation.Eur Radiol. 2024 Jan;34(1):525-537. doi: 10.1007/s00330-023-09998-y. Epub 2023 Aug 1. Eur Radiol. 2024. PMID: 37526668
-
The tumor burden score may be a discriminator in microwave ablation versus liver resection for hepatocellular carcinoma within the Milan criteria: a propensity score matching and inverse probability of treatment weighting study.Front Oncol. 2024 Feb 16;14:1330851. doi: 10.3389/fonc.2024.1330851. eCollection 2024. Front Oncol. 2024. PMID: 38434686 Free PMC article.
-
HMGB1/TREM1 crosstalk between heat-injured hepatocytes and macrophages promotes HCC progression after RFA.J Cancer Res Clin Oncol. 2024 Oct 28;150(10):480. doi: 10.1007/s00432-024-05996-9. J Cancer Res Clin Oncol. 2024. PMID: 39465435 Free PMC article.
-
Comparisons of Percutaneous Ablation, Open or Laparoscopic Liver Resection for Barcelona Clinic Liver Cancer Stage 0-A Hepatocellular Carcinoma: A Concurrent Generalized Propensity Score Analysis.J Hepatocell Carcinoma. 2024 Jul 25;11:1459-1472. doi: 10.2147/JHC.S477265. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39081686 Free PMC article.
References
-
- Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16:589–604.
-
- (KLCA) KLCA. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019; 20:1042–1113.
-
- Pompili M, De Matthaeis N, Saviano A, et al. Single hepatocellular carcinoma smaller than 2 cm: are ethanol injection and radiofrequency ablation equally effective? Anticancer Res 2015; 35:325–332.
-
- Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 2017; 66:1172–1173.
-
- European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69:182–236.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous